Here’s my ‘take aways’:
1) Board disappointment at FID and share price. But they think delay was ‘prudent’.
2) Reading between the lines, finance and divestment deals were in place if STO had said go. Seems they ran the process to the end and were happy with debt proposals.
3) NOPSEMA approval is supposed to be close, expected early 2023;
4) Divestment of Dorado asset in early 2023 and will be pre FID (this was asked and confirmed specifically);
5) Work on incorporating PAVO may be a factor is delayed FID, so that the low gas oil can be incorporated from beginning.
6) New drill targets yet to be selected. Other than Pavo South, no obvious next choice. Probably looking for more Gas to strengthen stage 2.
7) They are actively looking for new cash generating farm in opportunities and the cash is being protected for purchases. They are not interested in buy back of cap raise at this time.
happy to answer any specific questions…
- Forums
- ASX - By Stock
- CVN
- Ann: Annual General Meeting Presentation 2022
Ann: Annual General Meeting Presentation 2022, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CVN (ASX) to my watchlist
(20min delay)
|
|||||
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $295.1M |
Open | High | Low | Value | Volume |
16.0¢ | 16.5¢ | 15.5¢ | $339.0K | 2.104M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 87812 | 16.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.5¢ | 1054108 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 87812 | 0.160 |
22 | 1475582 | 0.155 |
13 | 1145574 | 0.150 |
22 | 821263 | 0.145 |
16 | 655495 | 0.140 |
Price($) | Vol. | No. |
---|---|---|
0.165 | 1034108 | 10 |
0.170 | 710593 | 17 |
0.175 | 374764 | 5 |
0.180 | 378884 | 10 |
0.185 | 152057 | 4 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
CVN (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online